Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
about
Androgen biosynthesis in castration-resistant prostate cancerCrystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate CancerCrystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancerIdentification of a gene signature of a pre-transformation process by senescence evasion in normal human epidermal keratinocytes.Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment libraryStraightforward protocol for the efficient synthesis of varied N(1)-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activitiesAldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.AKR1C3 as a target in castrate resistant prostate cancerApplication of the Pentafluorosulfanyl Group as a Bioisosteric Replacement.Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.Discovery of anthranilamides as a novel class of inhibitors of neurotropic alphavirus replication.Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.Rhodium-catalyzed direct C-H amination of benzamides with aryl azides: a synthetic route to diarylamines.Evaluation of Novel N-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells.
P2860
Q27026044-9FFD888C-AC28-4C77-B72E-6BB716867935Q27671816-DF65EA96-3A06-462D-A40D-7AC72DFFF192Q27676555-10955F2C-0CF6-4203-B6C7-EE3B19A45A38Q27678564-356420CB-397B-45CC-80E3-9182E733759CQ33786391-B8193DB2-2E67-4208-8D96-93CE35577CA1Q34375275-053CC743-5050-49DE-88A2-0B16A61FCE3FQ34498106-BAB0BED6-EDD2-42C2-B921-D3C60648583EQ35553876-1F832C04-E125-480D-94F3-AB0830A9A2B0Q35554014-91DA02CC-6AE2-400C-9B98-C21C513A2A29Q36055229-581A994E-057F-4915-9754-8369C09E796CQ36142192-844ABD3D-2483-427E-8491-E5AC3897870EQ36585622-1B17C584-E0B1-4BD3-8625-17BD29B243A9Q36937170-E36AFCB7-F5EA-417F-B876-7B5489E9D65FQ36970812-35993732-95FD-4999-BE2C-C47A5C0EE80FQ37248854-0702EF4F-6F76-4FCF-BD59-12C0193E2507Q38637720-445794BE-A532-4109-8D73-294F6C2C02D5Q38735379-53D6E9E8-986D-49EA-965F-9399CCE96587Q38754094-95BE0154-71D9-4DD0-959A-E3BBE80B4F30Q41449946-42B99AB6-1B40-4093-992D-27779BDF1670Q47587182-8108BC05-7044-4AB9-8D20-BBE9A73CB121Q47818730-7AED1965-0C2B-4AEB-B44A-B46374D69C49Q48251191-BD93C6D6-7764-4D9C-899F-B6D4B66610D6Q53363214-C80B3030-D175-4B87-9C87-4B6B83285FC6Q55069976-462C31ED-2A14-41BE-B3A5-12E4071FE4CE
P2860
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Development of potent and sele ...... ucture-activity relationships.
@ast
Development of potent and sele ...... ucture-activity relationships.
@en
type
label
Development of potent and sele ...... ucture-activity relationships.
@ast
Development of potent and sele ...... ucture-activity relationships.
@en
prefLabel
Development of potent and sele ...... ucture-activity relationships.
@ast
Development of potent and sele ...... ucture-activity relationships.
@en
P2093
P2860
P356
P1476
Development of potent and sele ...... ucture-activity relationships.
@en
P2093
Adegoke O Adeniji
Barry M Twenter
Jeffrey D Winkler
Michael C Byrns
Trevor M Penning
P2860
P304
P356
10.1021/JM201547V
P407
P577
2012-02-15T00:00:00Z